company background image
MRNA logo

Moderna NasdaqGS:MRNA Stock Report

Last Price

US$104.26

Market Cap

US$39.9b

7D

-6.9%

1Y

-32.5%

Updated

18 Mar, 2024

Data

Company Financials +

MRNA Stock Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.

MRNA fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Moderna, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Moderna
Historical stock prices
Current Share PriceUS$104.26
52 Week HighUS$163.24
52 Week LowUS$62.55
Beta1.6
1 Month Change17.98%
3 Month Change17.03%
1 Year Change-32.53%
3 Year Change-28.39%
5 Year Change437.42%
Change since IPO460.54%

Recent News & Updates

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Moderna: Counting On Pipeline Too Much

Feb 23

Recent updates

Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 27
Moderna, Inc. (NASDAQ:MRNA) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Moderna: Counting On Pipeline Too Much

Feb 23

Moderna: Highly Uncertain Future For mRNA Vaccine In A Post-Pandemic World

Feb 16

Moderna: Fade 2025 Outlook

Jan 15

Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Dec 29
Moderna, Inc. (NASDAQ:MRNA) Held Back By Insufficient Growth Even After Shares Climb 26%

Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Nov 03
Need To Know: The Consensus Just Cut Its Moderna, Inc. (NASDAQ:MRNA) Estimates For 2024

Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Oct 18
Moderna, Inc. (NASDAQ:MRNA) Shares Could Be 30% Below Their Intrinsic Value Estimate

Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?

May 23
Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 47% Discount?

Weak Statutory Earnings May Not Tell The Whole Story For Moderna (NASDAQ:MRNA)

Mar 03
Weak Statutory Earnings May Not Tell The Whole Story For Moderna (NASDAQ:MRNA)

Earnings Working Against Moderna, Inc.'s (NASDAQ:MRNA) Share Price Following 28% Dive

Feb 25
Earnings Working Against Moderna, Inc.'s (NASDAQ:MRNA) Share Price Following 28% Dive

Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 48% Discount?

Feb 08
Is Moderna, Inc. (NASDAQ:MRNA) Trading At A 48% Discount?

Shareholder Returns

MRNAUS BiotechsUS Market
7D-6.9%-2.1%0.5%
1Y-32.5%9.7%29.0%

Return vs Industry: MRNA underperformed the US Biotechs industry which returned 9.7% over the past year.

Return vs Market: MRNA underperformed the US Market which returned 29% over the past year.

Price Volatility

Is MRNA's price volatile compared to industry and market?
MRNA volatility
MRNA Average Weekly Movement8.7%
Biotechs Industry Average Movement11.9%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: MRNA's share price has been volatile over the past 3 months.

Volatility Over Time: MRNA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20105,600Stephane Bancelhttps://www.modernatx.com

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics.

Moderna, Inc. Fundamentals Summary

How do Moderna's earnings and revenue compare to its market cap?
MRNA fundamental statistics
Market capUS$39.92b
Earnings (TTM)-US$4.71b
Revenue (TTM)US$6.85b

5.8x

P/S Ratio

-8.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MRNA income statement (TTM)
RevenueUS$6.85b
Cost of RevenueUS$9.54b
Gross Profit-US$2.69b
Other ExpensesUS$2.02b
Earnings-US$4.71b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-12.31
Gross Margin-39.28%
Net Profit Margin-68.84%
Debt/Equity Ratio0%

How did MRNA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.